FERROSA, founded in Basel in 2026 by Forty51 Ventures, is developing a bispecific antibody against inflammatory anaemia. It has raised USD 3.5 million in seed funding to take its preclinical programme through to in vivo proof of concept.
- Announced on
- Round
- Seed
- Amount
- USD 3.5 M
- Location
- Basel, canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- Forty51 Ventures lead
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic